论文部分内容阅读
目的探讨唑来膦酸钠与阿仑膦酸钠治疗绝经后妇女骨质疏松的疗效。方法选取自2012年2月~2015年2月期间我院收治的绝经后妇女骨质疏松患者108例,唑来膦酸钠组52例,阿仑膦酸钠组56例。治疗前后测定骨密度、进行Roland-Morris和VAS评分,并判定疗效。结果治疗组总有效率为86.54%;对照组总有效率为75.00%,差异具有统计学意义(P<0.05)。两组患者腰椎L1~4、双髋及股骨颈的骨密度测定值治疗后与治疗前比较,差异均具有统计学意义(P<0.05)。两组患者治疗后腰椎L1~4及双髋骨密度比较差异具有统计学意义(P<0.05)。两组患者治疗后6及12个月VAS评分比较差异具有统计学意义(P<0.05)。两组患者治疗后6个月Roland-Morris评分比较差异具有统计学意义(P<0.05)。结论唑来膦酸钠治疗绝经后妇女骨质疏松症能够有效提高患者骨密度,治疗后疼痛程度及腰椎功能障碍显著减轻,其疗效明显优于阿伦磷酸钠,值得在临床上推广应用。
Objective To investigate the efficacy of sodium zoledronate and alendronate in the treatment of postmenopausal women with osteoporosis. Methods From Feb. 2012 to Feb. 2015, 108 cases of osteoporosis in postmenopausal women, 52 cases of zoledronic acid and 56 cases of alendronate were enrolled in our hospital. BMD was measured before and after treatment, Roland-Morris and VAS scores were evaluated, and the curative effect was evaluated. Results The total effective rate was 86.54% in the treatment group and 75.00% in the control group, the difference was statistically significant (P <0.05). The lumbar spine L1 ~ 4, double hip and femoral neck bone mineral density measured in both groups before and after treatment, the difference was statistically significant (P <0.05). Two groups of patients with lumbar spine after L1 ~ 4 and double hip density difference was statistically significant (P <0.05). There was significant difference in VAS scores between the two groups 6 and 12 months after treatment (P <0.05). Roland-Morris score was significantly different between the two groups at 6 months after treatment (P <0.05). Conclusion Zoledronic acid treatment of postmenopausal women with osteoporosis can effectively improve the patient’s bone mineral density, post-treatment pain and lumbar dysfunction was significantly reduced, the effect was significantly better than alendronate sodium, it is worth in the clinical application.